Susan Desmond-Hellmann, MD, M.P.H., serves as an independent board member at Pfizer Inc. She joined the company's board in 2020, bringing with her a wealth of experience in the healthcare and pharmaceutical industries. As an independent director, she provides unbiased guidance and oversight to the company's operations and strategic decisions. Desmond-Hellmann is a member of the Compensation, Governance, and Science and Technology Committees, where she contributes her expertise to help shape the company's policies and initiatives.

Prior to her role at Pfizer, Desmond-Hellmann had a distinguished career in the medical and pharmaceutical fields. She served as the Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 to 2020, where she played a pivotal role in advancing global health initiatives and combating diseases such as HIV/AIDS, malaria, and tuberculosis. Before that, she spent 14 years at Genentech, a leading biotechnology company, where she held various leadership positions, including President of Product Development and Chief Medical Officer. During her tenure at Genentech, she was instrumental in the development and approval of several groundbreaking cancer therapies.

Desmond-Hellmann's contributions to the field of medicine extend beyond her corporate roles. She is a board-certified oncologist and has held academic positions at the University of California, San Francisco (UCSF), where she served as the Chancellor from 2009 to 2014. As Chancellor, she focused on advancing the university's mission of research, education, and patient care. Desmond-Hellmann has received numerous awards and honors for her work, including being named one of Forbes' "100 Most Powerful Women" multiple times. Her expertise, leadership, and dedication to improving global health make her a valuable asset to Pfizer's board of directors.